Perkin-Elmer hooks up polymerase chain reaction (PCR) and sequencing for diagnostics
This article was originally published in Clinica
Executive Summary
Swiss pharmaceutical company Roche has granted Perkin-Elmer a licence to develop diagnostic systems using PCR. The agreement allows Perkin-Elmer to combine PCR with its electrophoresis-based DNA analysis systems. This is an extension of a previous licence which allows Perkin-Elmer's applied biosystems division to use PCR with its DNA analysis systems for research.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.